Pharmaceutical

Boehringer and Lilly gain FDA approval for kidney disease therapy

Boehringer and Eli Lilly have received approval from the US FDA for Jardiance to treat adults with chronic kidney disease (CKD).

Sep 25, 2023 - 20:00
Boehringer and Lilly gain FDA approval for kidney disease therapy
Boehringer and Eli Lilly have received approval from the US FDA for Jardiance to treat adults with chronic kidney disease (CKD).
Read the original article

Tags:

Previous Article

Merck and ICR enter renewed cancer drug discovery partnership

Next Article

A novel role discovered for vagus nerve

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

New definition of a human embryo proposed amid rapid scientific advances

New definition of a human embryo proposed amid rapid sc...

Aug 17, 2023

Cell and gene therapy companies must demonstrate strong value proposition for investment          

Cell and gene therapy companies must demonstrate strong...

Dec 7, 2024

STAT+: European regulators tout their accomplishments against pharma’s anticompetitive practices

STAT+: European regulators tout their accomplishments a...

Jan 30, 2024